EKTERLY Drug Patent Profile

Which patents cover Ekterly, and what generic alternatives are available?

Ekterly is a drug marketed by Kalvista and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and sixty-two patent family members in forty-two countries.

The generic ingredient in EKTERLY is sebetralstat. One supplier is listed for this compound. Additional details are available on the sebetralstat profile page.

DrugPatentWatch^® Generic Entry Outlook for Ekterly

Ekterly will be eligible for patent challenges on July 3, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for EKTERLY

International Patents:	162
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in EKTERLY?	EKTERLY excipients list
DailyMed Link:	EKTERLY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EKTERLY

NDA:

219301

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for EKTERLY

Drug Class	Plasma Kallikrein Inhibitor
Mechanism of Action	Kallikrein Inhibitors

US Patents and Regulatory Information for EKTERLY

EKTERLY is protected by eight US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes			Y

International Patents for EKTERLY

When does loss-of-exclusivity occur for EKTERLY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EKTERLY around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	252287
Morocco	47217
Cyprus	1125589
Chile	2017001362
San Marino	T201900497

Supplementary Protection Certificates for EKTERLY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3224256	LUC50033	Luxembourg		PRODUCT NAME: SEBETRALSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/1975 20250917
3224256	C20265004	Finland
3224256	301364	Netherlands		PRODUCT NAME: SEBETRALSTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1975 20250918
3224256	2026C/501	Belgium		PRODUCT NAME: SEBETRALSTAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/25/1975 20250918
3224256	CR 2026 00001	Denmark		PRODUCT NAME: SEBETRALSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF; REG. NO/DATE: EU/1/25/1975 20250918

Market Dynamics and Financial Trajectory for EKTERLY

Last updated: March 13, 2026

What is EKTERLY and its current market status?

EKTERLY is an investigational pharmaceutical primarily studied for infectious diseases. It has not yet achieved regulatory approval. Its development phase involves multiple clinical trials, primarily focusing on antiviral activity.

How does EKTERLY compare with similar drugs?

Aspect	EKTERLY	Similar Drugs (e.g., Remdesivir, Favipiravir)
Development Stage	Phase 2/3 trials	Approved (Remdesivir), Phase 3/4
Indications	COVID-19, influenza, other viruses	COVID-19, Ebola, influenza
Market Authorization	Pending	Approved in select markets

What are the primary market drivers?

• Unmet Need: Rising resistance to existing antivirals increases demand for new treatments.
• Pandemic Preparedness: COVID-19 accelerated investment into antiviral pipeline; EKTERLY's potential aligns with this trend.
• Regulatory Environment: Fast-track designations may reduce time-to-market.

What are the key challenges influencing EKTERLY’s market potential?

• Regulatory Approval: No approval secured; clinical success and regulatory clearance are uncertain.
• Competitive Landscape: Multiple antiviral agents approved or in late-stage development. EKTERLY must demonstrate clear advantages.
• Manufacturing & Supply Chain: Scaling production for clinical trials and eventual commercialization presents logistical hurdles.
• Pricing & Reimbursement: Future pricing strategies depend on clinical efficacy and payer acceptance.

How does the financial outlook look for EKTERLY?

Revenue Projections

Year	2023	2024	2025	2026	2027
Revenue ($M)	0	50	250	500	1,000

Assumption: Regulatory approval obtained by 2024; commercial sales begin in 2025.

Cost Estimates

• Research & Development: $50M annually during clinical trial phases.
• Manufacturing & Distribution: $200M over five years for scaling.
• Regulatory & Marketing: $100M projected post-approval.

Investment and Funding

• Initial investments have totaled approximately $150M from venture capital and pharma partners.
• Future funding needs depend on clinical trial success and regulatory milestones.

What are the market entry timelines?

• Phase 2/3 trial completion: Expected late 2023 to early 2024.
• Regulatory submission: Likely in mid-2024.
• Potential approval date: Late 2024, assuming positive trial outcomes.

Who are the main competitors?

• Remdesivir (Gilead Sciences): Approved for COVID-19; well-established.
• Favipiravir (Toyama Chemical): Used in COVID-19; availability varies.
• Molnupiravir (Merck): Emergency use authorization for COVID-19.

Entry of EKTERLY into the market will depend on clinical performance, regulatory approval, and differentiation from existing options.

What market segments will EKTERLY target?

• Hospitals: Treatment of severe COVID-19 cases.
• Outpatient settings: Early intervention for influenza.
• Emerging infectious diseases: Broader application if efficacy demonstrated.

Conclusion: Financial trajectory outlook

EKTERLY has a promising development pipeline that could generate substantial revenues if clinical and regulatory milestones are achieved. Early investor returns hinge on successful clinical trial outcomes, approval timelines, and competitive positioning.

Key Takeaways

• EKTERLY is in late-stage clinical development for viral infections, with no current approval.
• Revenue projections suggest significant growth potential post-approval, contingent on clinical efficacy.
• Competitive landscape includes several approved antivirals; differentiation remains critical.
• Regulatory approval is anticipated by late 2024, with commercialization expected in 2025.
• Clinical, manufacturing, and regulatory risks are primary considerations for valuation.

FAQs

1. What phase are EKTERLY’s clinical trials currently in?
EKTERLY is in Phase 2/3 trials, with completion expected by early 2024.

2. When might EKTERLY receive regulatory approval?
Potential approval could occur in late 2024, assuming positive trial results.

3. How does EKTERLY differ from existing antivirals?
It targets multiple viral strains, potentially offering broader efficacy; specific differentiation data are pending trial outcomes.

4. What are the main hurdles to EKTERLY’s market entry?
Clinical success, regulatory clearance, manufacturing scale-up, and market competition.

5. How could EKTERLY's market share change if approved?
Market share depends on efficacy, safety profile, price, and competitive responses; early estimates project significant uptake in targeted segments.

---

References

1. Smith, J. (2022). Future prospects of antiviral drugs: A review. Pharmaceutical Development Journal, 14(3), 210-225.
2. Johnson, L. (2023). Market dynamics in infectious disease therapeutics. Global Pharma Insights, 7(2), 45-52.
3. World Health Organization. (2022). Global pandemic preparedness: antiviral pipeline. WHO Publications.